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MaOBJECTIVES The aim of this study was to investigate the correlation between in-stent neointimal tissue without
features of neoatherosclerosis and long-term clinical outcomes.
BACKGROUND Recent studies have reported differential morphological characteristics of in-stent neointimal tissue
assessed by optical coherence tomography (OCT).
METHODS The study population consisted of 336 patients with 368 drug-eluting stent-treated lesions. Patients
received a follow-up OCT examination without any intervention. OCT-based neointima was categorized as homogeneous
(n ¼ 227 lesions in 208 patients), heterogeneous (n ¼ 79 lesions in 73 patients), or layered (n ¼ 62 lesions in 55 patients).
Major adverse cardiac events (MACE) (a composite of cardiac death, nonfatal myocardial infarction, or target lesion
revascularization) were assessed according to neointimal patterns during long-term clinical follow-up after OCT
examination.
RESULTS The time interval between stent implantation and OCT examination was similar among the 3 groups
(p ¼ 0.64). On multivariate logistic regression analysis, the signiﬁcant determinant for the heterogeneous neo-
intima was age (odds ratio [OR]: 1.037, 95% conﬁdence interval [CI]: 1.007 to 1.068, p ¼ 0.015) and an initial
clinical presentation of acute coronary syndrome (OR: 1.967, 95% CI: 1.159 to 3.339, p ¼ 0.012). The overall
median follow-up duration for all patients after follow-up OCT examination was 31.0 months, and this was
statistically different among the heterogeneous group (22.0 months), the homogeneous group (34.0 months), and
the layered group (28.0 months, overall p ¼ 0.002). MACE occurred more frequently in patients with hetero-
geneous neointima over a median 31-month follow-up period after OCT examination (13.7% vs. 2.9% in homo-
geneous vs. 7.3% in layered, p ¼ 0.001). A propensity score–adjusted Cox regression analysis showed that
independent risk factors for MACE were inclusion in the heterogeneous neointima (hazard ratio: 3.925, 95% CI:
1.445 to 10.662, p ¼ 0.007) and minimal lumen cross-sectional area (hazard ratio: 0.368, 95% CI: 0.242
to 0.560, p < 0.001).
CONCLUSIONS Determination of neointimal characteristics is helpful in predicting long-term clinical outcomes. Our
data suggest that heterogeneous lesions are linked to poor long-term clinical prognoses. (J Am Coll Cardiol Img
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ABB R E V I A T I O N S
AND ACRONYMS
CI = conﬁdence interval
CSA = cross-sectional area
DES = drug-eluting stent(s)
IQR = interquartile range
MACE = major adverse
cardiac event(s)
OCT = optical coherence
tomography
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789P athological studies have demonstrated thatneointima within a stent comprises various tis-sue components including collagen, proteogly-
can, smooth muscle, ﬁbrin, and thrombus (1–3).
However, previous imaging modalities, such as angi-
ography and intravascular ultrasound, have a limited
ability to assess the neointimal characteristics due to
low resolution. Intravascular optical coherence to-
mography (OCT) has higher resolution and is useful
for the qualitative as well as quantitative evaluation
of neointimal tissue (4,5). Recent OCT studies have
reported differential morphological characteristics of
neointimal tissue, which correlated well with his-
tological ﬁndings (4,6,7). Furthermore, the athero-
sclerotic change (neoatherosclerosis) of neointimal
tissue inside a stent is now thought to be an underly-
ing mechanism of late stent failure (8,9). However,
the relationship between different OCT-based neoin-
timal tissue without features of neoatherosclerosis
and long-term clinical outcomes has not been inves-
tigated. Therefore, the aim of this study was to inves-
tigate the correlation between in-stent neointimal
characteristics without features of neoatherosclerosis
as assessed by OCT and long-term clinical outcomes.SEE PAGE 796METHODS
STUDY PATIENTS AND DESIGN. This study was
approved by the institutional review board of our
institution, and written informed consent was ob-
tained from each patient. From the follow-up OCT
registry database of our institution, a total of 336
patients with 368 drug-eluting stent (DES)-treated
lesions with a neointimal thickness of at least 100 mm
in 5 consecutive cross-sectional images at the time of
follow-up OCT examination between January 2008
and October 2012 were included in this study.
Because lesions with mild to moderate neointimal
proliferation <50% of angiographic diameter stenosis
by visual estimation were exclusively selected for
long-term clinical follow-up after follow-up OCT
examination, none of these lesions required further
intervention at the follow-up OCT examination.
Therefore, lesions treated with target-lesion revascu-
larization due to in-stent restenosis with signiﬁcant
narrowing at the time of follow-up OCT examination
were excluded from this study. In addition, lesions
with OCT-based evidence of neoatherosclerosis were
also excluded. The type of stent type selected was
at the discretion of the physician at the time of coro-
nary intervention. Patients were treated with 86
sirolimus-eluting stents (Cypher, Cordis, Miami Lakes,Florida), 39 paclitaxel-eluting stents (Taxus,
Boston Scientiﬁc, Natick, Massachusetts), 147
zotarolimus-eluting stents (Endeavor Sprint
or Resolute, Medtronic, Santa Rosa, Califor-
nia), 62 everolimus-eluting stents (Xience,
Abbott Vascular, Abbott Park, Illinois), and 34
biolimus-eluting stents (Nobori, Terumo Cor-
poration, Tokyo, Japan). The ﬁrst-generation
DES was deﬁned as a sirolimus- (Cypher)
and paclitaxel- (Taxus) eluting stent and
the second-generation DES as zotarolimus-
(Endeavor Sprint or Resolute), everolimus- (Xience),
and biolimus- (Nobori) eluting stents. DES implanta-
tion was performed using conventional techniques.
Unfractionated heparin was administered as an initial
bolus of 100 IU/kg, with additional boluses adminis-
tered during the procedure to achieve an activated
clotting time of 250 to 300 s. Dual antiplatelet therapy
(aspirin and clopidogrel) was recommended to all
patients for at least 12 months after DES implantation.
General inclusion and exclusion criteria of follow-up
OCT procedures were previously reported (10). At
the time of OCT follow-up, the clinical presentation
of the patients was as follows: 7 patients had acute
coronary syndrome, 25 patients had stable angina,
and 304 patients were asymptomatic. The reasons
for follow-up angiography were: 1) evidence of
myocardial ischemia by stress test or clinical presen-
tation of coronary artery disease (n ¼ 32, 9.5%); or
2) planned routine follow-up angiography (n ¼ 304,
90.5%).
A major adverse cardiac event (MACE) was deﬁned
as cardiovascular death, nonfatal myocardial infarc-
tion, and target-lesion revascularization. Clinical
events were deﬁned according to the Academic
Research Consortium (11). All deaths were consi-
dered cardiovascular deaths unless a deﬁnite non-
cardiovascular cause was established. Myocardial
infarction was deﬁned as the presence of clinical
symptoms, electrocardiographic changes, or ab-
normal imaging ﬁndings of myocardial infarction
combined with an increase in creatine kinase-
myocardial band fraction >3 times the upper limit
of the normal range or an increase in troponin
T/troponin I to more than the 99th percentile of the
upper limit of normal, all of which were unrelated to
an interventional procedure (11,12). Stent thrombosis
was deﬁned according to the recommendations of the
Academic Research Consortium (11,13). Target-lesion
revascularization was deﬁned as a repeat percuta-
neous intervention or bypass surgery of the target
lesions with either of the following ﬁndings: ischemic
symptoms or a positive stress test and an angio-
graphic minimal lumen diameter stenosis $50%
Kim et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 8 , 2 0 1 4
OCT-Based Neointima A U G U S T 2 0 1 4 : 7 8 8 – 9 5
790assessed by quantitative coronary angiographic
analysis or an angiographic diameter stenosis $70%
assessed by quantitative coronary angiographic
analysis without either ischemic symptoms or a pos-
itive stress test.
OCT PROCEDURE AND ANALYSIS. OCT was per-
formed with either the Model M2 imaging system
or the C7-XR imaging systems (LightLab Imaging,
Inc./St. Jude Medical, St. Paul, Minnesota). In the
former system (Model M2), the occlusion catheter was
positioned proximal to the stent and a 0.014-inch
wire-type imaging catheter was positioned distal to
the stent. During image acquisition, the occlusion
balloon (Helios, Avantec Vascular Corp., Sunnyvale,
California) was inﬂated to 0.4 to 0.6 atm and lactated
Ringer’s solution was infused at 0.5 to 1.0 ml/s. The
imaging wire was pulled from distal to proximal with
a motorized pull-back system at 1.0 mm/s (10). The
frequency-domain OCT system (Model C7-XR) was
developed to generate frames at much higher rates,
thereby allowing for faster pullback speeds. OCT im-
ages were generated at 100 frames/s, whereas the
catheter was pulled back at 20 mm/s. A contrast
medium was continuously ﬂushed through a guiding
catheter at a rate of 4 to 5 ml/s for 3 to 4 s. Continuous
images were acquired and stored digitally for subse-
quent analysis.
All OCT images were analyzed at a core laboratory
(Cardiovascular Research Center, Seoul, Republic of
Korea) by analysts who were blinded to both pa-
tient and procedural information. Cross-sectional
OCT images were analyzed at 1-mm intervals for
quantitative measurements. Stent area and luminal
cross-sectional area (CSA) were measured, and neo-
intimal CSA was calculated as the stent CSA minus the
luminal CSA. The segment with minimal lumen areaFIGURE 1 Representative Optical Coherence Tomography Images of
Homogeneous type (A), heterogeneous type (B), layered type (C).and greatest neointimal proliferation could be the
representative site of the lesions for long-term clin-
ical follow-up. Therefore, the stented segments at the
minimal lumen CSA and greatest neointimal CSA
were assessed qualitatively to characterize the neo-
intimal tissue as: 1) homogeneous neointima, a uni-
form signal-rich band without focal variation or
attenuation; 2) heterogeneous neointima, focally
changing optical properties and various backscat-
tering patterns; and 3) layered neointima, layers with
different optical properties (i.e., an adluminal high-
scattering layer and an abluminal low-scattering
layer) (Fig. 1) (4,6,14). The interobserver and intra-
observer agreements for the assessment of neo-
intimal tissue morphology in our laboratory were
previously reported (15).
STATISTICAL ANALYSIS. Statistical analysis was
performed using PASW (version 18.0.0, SPSS Inc.,
Chicago, Illinois). Data are expressed as n (%), mean 
SD, or median (interquartile range [IQR]). Compari-
sons of categorical data were made using chi-square
statistics or the Fisher exact test. Continuous vari-
ables were compared using 1-way analysis of variance
or the Kruskal-Wallis test. Event-free survivals were
analyzed by Kaplan-Meier survival curves, and the
differences between event-free survival curves were
compared with the log-rank test. Then, considering
the survival curves, layered and homogeneous neo-
intimas were grouped together to be compared with
the heterogeneous neointima. Grouping layered and
homogeneous neointimas was done a posteriori.
Multivariate logistic analysis with use of generalized
estimating equations was performed to determine
the independent risk factors for heterogeneous
neointima. The variables with a p value <0.2 on uni-
variate analysis and traditional cardiac risk factorsNeointimal Tissue
TABLE 1 Clinical, Angiographic, and Optical Coherence Tomography Characteristics
Homogeneous
Group
Heterogeneous
Group
Layered
Group p Value
Time interval to OCT, months 9.0 (4.5–10.0) 8.0 (5.0–10.0) 9.0 (6.0–11.0) 0.64
Clinical variables 208 Patients 73 Patients 55 Patients
Age, yrs 60.8  9.6 64.0  7.9 63.5  7.9 0.014
Male 134 (64.4) 52 (71.2) 39 (70.9) 0.45
Diabetes mellitus 58 (27.9) 24 (32.9) 22 (40.0) 0.21
Hypertension 125 (60.1) 40 (54.8) 36 (65.5) 0.47
Dyslipidemia 95 (45.7) 25 (34.2) 25 (45.5) 0.22
Current smoker 39 (18.8) 19 (26.0) 15 (27.3) 0.24
Chronic renal failure 3 (1.4) 1 (1.4) 0 (0.0) 0.67
Clinical presentation at index
procedure
0.10
Stable angina 117 (56.3) 31 (42.5) 32 (58.2)
Acute coronary syndrome 91 (43.8) 42 (57.5) 23 (41.8)
Medications
Aspirin 208 (100.0) 73 (100.0) 55 (100.0) 1.00
Clopidogrel 208 (100.0) 73 (100.0) 55 (100.0) 1.00
Beta-blocker 170 (81.7) 55 (75.3) 46 (83.6) 0.41
ACE inhibitor or ARB 146 (70.2) 50 (68.5) 39 (70.9) 0.95
Calcium channel blocker 66 (31.7) 19 (26.0) 19 (34.5) 0.54
Statin 194 (93.3) 65 (89.0) 52 (94.5) 0.41
Angiographic variables 227 Lesions 79 Lesions 62 Lesions
Target coronary artery 0.033
Left anterior descending 117 (51.5) 46 (58.2) 28 (45.2)
Left circumﬂex 58 (25.6) 14 (17.7) 9 (14.5)
Right 52 (22.9) 19 (24.1) 25 (40.3)
Stent types 0.69
First-generation
drug-eluting stent
74 (32.6) 30 (38.0) 21 (33.9)
Second-generation
drug-eluting stent
153 (77.4) 49 (62.0) 41 (66.1)
Stent diameter, mm 3.0  0.3 3.1  0.4 3.0  0.4 0.13
Total stent length, mm 24.1  6.2 21.4  6.4 23.6  6.6 0.006
OCT variables 227 Lesions 79 Lesions 62 Lesions
Total frames 5,380 1,649 1,386
OCT system 0.10
Old OCT (M2) 172 (75.8) 50 (63.3) 44 (71.0)
New OCT (C7) 55 (24.2) 29 (36.7) 18 (29.0)
Quantitative
Mean stent CSA, mm2 7.1  1.9 7.1  2.1 7.3  1.8 0.60
Mean neointimal CSA, mm2 1.2  0.7 1.4  0.9 1.9  1.2 <0.001
Mean lumen CSA, mm2 5.9  1.7 5.7  1.9 5.5  1.7 0.19
Minimal lumen CSA, mm2 4.5  1.6 4.0  1.9 3.7  1.8 0.001
Neointimal thickness, mm 138  68 168  119 217  133 <0.001
Neointimal CSA stenosis, % 16.5  8.1 20.1  12.9 25.4  13.7 <0.001
Uncovered stent strut, % 3.4  5.4 4.7  8.0 4.1  7.3 0.29
Values are median (interquartile range), mean  SD, or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CSA¼ cross-sectional area; OCT¼
optical coherence tomography.
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791(age and sex) were entered into the multivariate
regression model. A propensity score for heteroge-
neous versus nonheterogeneous neointima was then
calculated (C-statistics ¼ 0.646, 95% conﬁdence in-
terval [CI]: 0.571 to 0.721). The propensity score was
used as a covariate in Cox proportional hazard models
along with minimal lumen CSA. Cox regression anal-
ysis was used to determine the propensity-adjusted
risk of MACE during follow-up for patients with het-
erogeneous versus nonheterogeneous neointima. A p
value <0.05 was considered statistically signiﬁcant.
RESULTS
Of the total 368 lesions included in this study, 79
were categorized as heterogeneous (21.5% of total
lesions) in 73 patients, and 227 in 208 patients and
62 in 55 patients were categorized as homogeneous
and layered, respectively. During the course of this
study, using the same criteria to deﬁne mild to
moderate neointimal hyperplasia, there were 3
additional cases meeting the OCT criteria of neo-
atherosclerosis that were excluded from the 368
study lesions. Baseline characteristics among the 3
groups are listed in Table 1. Mean age was older in
the heterogeneous and layered groups. An initial
clinical presentation of acute coronary syndrome at
the time of stent implantation was more frequently
observed in the heterogeneous group compared
with the nonheterogeneous group (57.5% vs. 43.3%,
p ¼ 0.032). The prevalence of ﬁrst-generation DES
was not different among the 3 groups. The median
time interval from stent implantation to OCT exam-
ination was similar in the 3 groups: 8.0 months, IQR:
5.0 to 10.0 months in the heterogeneous group
versus 9.0 months, IQR: 4.5 to 10.0 months in the
homogeneous group, and 9.0 months, IQR: 6.0 to
11.0 months in the layered group, p ¼ 0.64. The mean
neointimal CSA was greater and minimal lumen
CSA was smaller in the layered group (p < 0.001,
respectively).
Using multivariate logistic regression analysis, the
signiﬁcant determinants for the heterogeneous group
were age (odds ratio [OR]: 1.037, 95% CI: 1.007 to
1.068, p ¼ 0.015) and an initial clinical presentation
of acute coronary syndrome (OR: 1.967, 95% CI: 1.159
to 3.339, p ¼ 0.012) (Table 2). The overall median
follow-up duration for all patients after follow-up
OCT examination was 31.0 months (IQR: 16.0 to 44.0
months), and this was statistically different among
the heterogeneous group (median 22.0 months;
range 12.5 to 37.0 months), the homogeneous group
(median 34.0 months; range 17.0 to 46.8 months) and
layered group (median 28.0 months; range 17.0 to40.0 months; overall p ¼ 0.002). MACE occurred more
frequently in the heterogeneous group (13.7% vs.
2.9% in the homogeneous group vs. 7.3% in the
layered group, p ¼ 0.001 (Table 3, Fig. 2). In 3 patients
with neoatherosclerosis who were excluded from
this study, MACE did not occur during a median of
TABLE 2 Independent Predictors of the Heterogeneous Group on Follow-Up
Optical Coherence Tomography
Univariate Analysis Multivariate Analysis
OR (95% CI) p Value OR (95% CI) p Value
Age, per yrs 1.032 (1.003–1.062) 0.029 1.037 (1.007–1.068) 0.015
Male 1.046 (0.616–1.775) 0.87 1.131 (0.647–1.979) 0.67
First-generation drug-eluting
stent
1.125 (0.662–1.912) 0.66
Initial clinical presentation
of ACS
1.874 (1.130–3.107) 0.015 1.967 (1.159–3.339) 0.012
Diabetes mellitus 1.289 (0.758–2.190) 0.35
Hypertension 0.831 (0.503–1.373) 0.47
Dyslipidemia 0.662 (0.395–1.109) 0.12 0.746 (0.433–1.282) 0.29
Chronic renal failure 0.913 (0.101–8.290) 0.94
Time interval to OCT, months 1.015 (1.002–1.028) <0.001 1.012 (0.999–1.025) 0.07
Uncovered stent struts, per % 1.024 (0.989–1.061) 0.18 1.024 (0.988–1.061) 0.19
Stent diameter, per mm 1.258 (0.618–2.580) 0.53
Stent length, per mm 0.975 (0.938–1.014) 0.21
ACE inhibitor/ARB use 0.955 (0.555–1.642) 0.87
Statin use 0.625 (0.263–1.485) 0.29
ACS ¼ acute coronary syndrome; CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
TABLE 3 Major Adve
Optical Coherence To
Major Adverse C
A composite of cardiac
myocardial infarctio
revascularization
Cardiac death
Nonfatal myocardial in
Target-lesion revascula
Stent thrombosis
Values are n (%).
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79212.0 months. In a propensity-adjusted Cox propor-
tional hazards regression model, both heterogeneous
tissue type (hazard ratio: 3.925, 95% CI: 1.445 to
10.662, p ¼ 0.007) and minimal lumen CSA (hazard
ratio: 0.368, 95% CI: 0.242 to 0.560, p < 0.001)
(Table 4) were independent predictors of MACE.
DISCUSSION
Heterogeneous neointima were detected in 21.5% of
DES-treated lesions in the study population. The
occurrence of neointimal tissue in this group was
signiﬁcantly associated with both advanced age and
initial clinical presentation of acute coronary syn-
drome. MACE occurred more frequently in patients in
the heterogeneous group compared with those in
the nonheterogeneous group during the average
31-month follow-up period (13.7% vs. 2.9% in therse Cardiac Events During Follow-Up After Follow-Up
mography Examination
ardiac Events
Homogeneous
(n ¼ 208)
Heterogeneous
(n ¼ 73)
Layered
(n ¼ 55) p Value
death, nonfatal
n, or target lesion
6 (2.9) 10 (13.7) 4 (7.3) 0.001
1 (0.5) 0 (0.0) 0 (0.0) 0.78
farction 0 (0.0) 3 (4.1) 0 (0.0) <0.001
rization 5 (2.4) 7 (9.6) 4 (7.3) 0.020
1 (0.5) 3 (4.1) 0 (0.0) 0.006homogeneous group vs. 7.3% in the layered group,
p ¼ 0.001). In addition, we found that inclusion in the
heterogeneous group and minimal lumen CSA on
follow-up OCT examination were independent risk
factors for future MACE. To the best of our knowl-
edge, this is the ﬁrst study to investigate the clinical
signiﬁcance of neointimal tissue patterns without
features of neoatherosclerosis. Our data suggest that
the heterogeneous neointimal tissue pattern is
correlated with poor long-term clinical outcomes.
OCT is a valuable intravascular imaging modality
for assessing stent strut apposition and coverage. It
has 10 times higher resolution than intravascular ul-
trasound, thereby providing detailed information on
the vascular structure and stent (14). Additionally,
OCT is able to take advantage of the differential op-
tical properties of the neointima components and is
useful for evaluating the tissue characteristics after
stent implantation (4). For example, the optical
properties of neointima rich in smooth muscle cells
and collagen ﬁbers results in high backscattering to
optical waves and a high optical density. However,
neointima-rich proteoglycan, ﬁbrinoid, or organized
thrombi with few smooth muscle cells results in a low
optical intensity (16,17). The layered neointimal
pattern consists of 2 distinct layers. The inner layer
has a high optical density enriched with smooth
muscle cells and collagen, and the outer layer has a
low optical density consistent with ﬁbrinoid tissue
and inﬂammation surrounding the struts (17,18).
Comparing neointima with a marked signal attenua-
tion or a poor signal region assessed by OCT in the
late period after bare metal stent implantation ($5
years), histopathological ﬁndings of the neointima in
the same regions showed atherosclerotic changes in
the neointima consisting of cholesterol crystals,
foaming macrophages, and smooth muscle cells with
collagen ﬁbers (9).
The heterogeneous neointima in the present study
were mostly speckled in pattern. This is similar to
previous data examining in-stent restenotic lesions
within 1 year after the index procedure (19). Histo-
pathological studies have demonstrated that in-stent
restenotic tissue with a speckled pattern exhibited
myxomatous neointimal tissue that decreased with
time after bare metal stent implantation (2,17). How-
ever, the risk factors for the development of hetero-
geneous neointima have not been sufﬁciently
elucidated. Using multivariate analysis, we show here
that both advance age and initial clinical presentation
of acute coronary syndrome are independent risk
factors for the development of heterogeneous neo-
intimal tissue. These ﬁndings suggest that the initial
clinical presentation of acute coronary syndrome may
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Homogeneous vs. heterogeneous; p = 0.001
Heterogeneous vs. layered; p = 0.46
Homogeneous vs. layered; p = 0.04
Homogeneous (n) 208 193 140 108 64 21
           Layered (n) 55 50 36 24 11 1
Heterogeneous (n) 73 62 34 24 12 2
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FIGURE 2 Kaplan-Meier Curves According to Neointimal Pattern
Kaplan-Meier major adverse cardiac event (MACE)-free survival after optical coherence tomography (OCT) examination among homogeneous,
heterogeneous, and layered patterns (A) and between heterogeneous versus nonheterogeneous patterns (B). The nonheterogeneous group
included homogeneous and layered neointima, with a median of 31.0 (interquartile range: 16 to 44) months of follow-up. (A) Homogeneous
group versus heterogeneous group (p ¼ 0.001); heterogeneous group versus layered group (p ¼ 0.46); homogeneous group versus layered
group (p ¼ 0.04). (B) Nonheterogeneous group versus heterogeneous group (p ¼ 0.001).
TABLE 4 Analysis of a Composite of Cardiac Death, Nonfatal Myocardial Infarction,
or Target-Lesion Revascularization
Univariate Analysis
Propensity Score–Adjusted
Cox Regression Analysis
HR (95% CI) p Value HR (95% CI) p Value
Age, per yrs 1.006 (0.959–1.055) 0.81
Male 0.931 (0.371–2.333) 0.88
Hypertension 0.688 (0.286–1.652) 0.40
Diabetes mellitus 1.881 (0.779–4.539) 0.16
Dyslipidemia 0.953 (0.389–2.332) 0.92
Current smoking 1.499 (0.576–3.901) 0.41
Initial clinical presentation
of ACS
1.586 (0.648–3.884) 0.31
First-generation
drug-eluting stent
2.440 (0.980–6.075) 0.06
Time interval to OCT,
months
1.018 (1.003–1.033) 0.017
Minimal lumen CSA,
per mm2
0.325 (0.211–0.501) <0.001 0.368 (0.242–0.560) <0.001
Stent diameter, per mm 1.207 (0.322–4.523) 0.78
Stent length, per mm 1.024 (0.954–1.098) 0.51
Heterogeneous group 4.236 (1.759–10.200) 0.001 3.925 (1.445–10.662) 0.007
Abbreviations as in Table 2.
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793be associated with the formation of immature neo-
intima after stent implantation due to underlying
unstable plaque characteristics. A pathological study
reported that underlying unstable plaques were
identiﬁed as one of the independent risk factors
for neoatherosclerosis (20). It has also been shown
that clinical presentation at the onset of in-stent
restenosis is associated with different patterns of
neointimal characteristics. Gonzalo et al. (4) demon-
strated that the incidence of heterogeneous neo-
intima in patients presenting with stable angina was
6.7% (1 of 15) versus 40% (4 of 10) in patients with
unstable angina (p ¼ 0.08) (4). Neoatherosclerosis, as
traditionally deﬁned by OCT, was rarely observed in
patients with mild to moderate neointimal hyperpla-
sia, occurring in 3 patients (<1%) in our study.
Because we observed only 3 such patients, additional
studies are required to determine the long-term out-
comes of such patients.
Although the quantitative growth of neointimal
tissue and stent underexpansion were important
factors for the occurrence of MACE after stent im-
plantation, the qualitative pattern of neointimal
characteristics might be also a possible prognostic
parameter. The response of balloon angioplasty in in-
stent restenotic lesions could be different accordingto neointimal characteristics such as the homoge-
neous, heterogeneous, or layered pattern because of
differential histopathological components of these
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794tissues (18,21). Atherosclerotic changes or disease
progression of the neointima might increase plaque
vulnerability and accumulation, ultimately leading to
a similar pathophysiology of the native lesion.
However, the clinical implication of neointimal
characteristics in DES-treated lesions without signif-
icant narrowing and the need for subsequent inter-
vention has not been investigated. In this study, we
found the appearance of heterogeneous neointima to
be an independent risk factor for MACE. This was true
even in lesions without signiﬁcant narrowing. The
DES-treated lesions were divided into 3 groups in the
present study: heterogeneous, homogeneous, and
layered groups. In contrast to homogeneous or
layered neointima, immature neointima and the lack
of endothelial cells in the heterogeneous neointima
might actually enhance the formation of atheroscle-
rotic changes and be related to MACE. It is possible
that the heterogeneous pattern is a precursor to
neoatherosclerosis, explaining the increased MACE
rate during follow-up. Because we did not perform
serial OCT examinations, further study is required to
examine this hypothesis.
STUDY LIMITATIONS. First, we included only pa-
tients with DES-treated lesions $100 mm of neo-
intimal thickness and mild to moderate neointimal
proliferation <50% of angiographic diameter steno-
sis. Therefore, the results in this study can be only
applicable to lesions with mild to moderate neo-
intimal proliferation at the time of follow-up OCT.
Patients in whom only follow-up OCT was performed
were included. This may have potential for selection
bias. However, these lesions provided an adequate
amount of neointimal tissue for accurate quantitative
and qualitative OCT analysis. Second, the neointimal
tissue characteristics need to be validated withhistology, and the current intravascular OCT system
may be limited in its ability to properly evaluate the
qualitative characteristics of the neointima. In addi-
tion, the heterogeneous or layered pattern may partly
overlap with patterns of neoatherosclerosis, which
could be a methodological concern in current OCT
technology. Third, the interval between stent im-
plantation and OCT examination varied in the study
population. Therefore, multivariate analysis was
applied to control the different stent age. Fourth, the
layered pattern appeared to confer a risk of long-term
MACE intermediate between the heterogeneous and
homogenous patterns. Finally, because of relatively
few MACE events, we were unable to determine other
independent predictors of MACE beyond heteroge-
neous tissue type and minimal lumen CSA. Given the
modest number of events, further study is required to
examine this issue.
CONCLUSIONS
Long-term clinical outcomes may vary with the
qualitative neointimal tissue characteristics assessed
at follow-up by OCT examination. Our data suggest
that the neointimal tissue pattern in the heteroge-
neous group is related to a poor long-term clinical
prognosis. These ﬁndings strongly suggest the need
for further, large, randomized registry studies to
validate the effect of neointimal classiﬁcation by
OCT on long-term clinical outcomes.
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